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Abstract
Background
A substantial number of patients with chronic low back pain (CLBP) have axial spondyloar-
thritis (axSpA), but early recognition of these patients is difficult for general practitioners
(GPs). The Case Finding Axial Spondyloarthritis (CaFaSpA) referral strategy has shown to
be able to identify patients with CLBP at risk for axSpA, but its impact on clinical daily prac-
tice is yet unknown.
Objective
To assess the effect of the CaFaSpA referral strategy on pain caused by disability in primary
care patients with CLBP.
Methods
Within this clustered randomized controlled trial 93 general practices were randomized to
either the CaFaSpA referral model (intervention) or usual primary care (control). In each
group primary care patients between 18 and 45 years with CLBP were included. The pri-
mary outcome was disability caused by CLBP, measured with the Roland Morris Disability
Questionnaire (RMDQ) at baseline and four months. Secondary outcome was the frequency
of new axSpA diagnosis. Descriptive analyses were performed, and a linear mixed-effects
model was used.
Results
In total 679 CLBP patients were included of which 333 patients were allocated to the inter-
vention group and 346 to the control group. Sixty-four percent were female and mean age
was 36.2 years. The mean RMDQ score at baseline was 8.39 in the intervention group and
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8.61 in the control group. At four months mean RMDQ score was 7.65 in the intervention
group and 8.15 in the control group. This difference was not statistically significant (p =
0.50). Six (8%) out of the 75 finally referred patients, were diagnosed with axSpA by their
rheumatologist.
Conclusions
The CaFaSpA referral strategy for axSpA did not have an effect on disability after four
months caused by CLBP. However, the strategy is able to detect the axSpA patient within
the large CLBP population sufficiently.
Trial registration number: NCT01944163, Clinicaltrials.gov.
Introduction
Axial spondyloarthritis (axSpA) is a chronic disabling rheumatic disease for which the leading
symptom is chronic low back pain (CLBP). [1] The prevalence of axSpA among CLBP patients
varies between 5 to 71% depending on the setting where these studies have been performed.
AxSpA prevalence is 5–24% in primary care [2–4] and 32–71% in secondary care [5–8]. Previ-
ous research has shown that early diagnosis and treatment of axSpA leads to better treatment
outcomes. [9,10] The time between disease onset and diagnosis of axSpA however, is estimated
to be around 8–10 years. [9,11] This delay may cause disabilities, a reduced quality of life and
affect work participation. [12] Therefore, early recognition of axSpA patients from all CLBP is
crucial. [13,14] In most countries CLBP patients are first seen and managed by general practi-
tioners (GPs) or physical therapists. Therefore, GPs should be able to recognize the ‘red flags’
for axSpA. Early recognition seems difficult in primary care (PC) since the prevalence of CLBP
is high and GPs’ awareness of SpA features are low. Worldwide 19% of patients (age 20–59
years) suffer from CLBP. [15] As a result, several referral strategies have been developed to
help physicians identify patients at risk for axSpA within these CLBP patients. [16–19] Most
referral strategies however, were developed in secondary care patients and have not been exter-
nally validated. Moreover, the effect of implementing these algorithms on outcomes from a
patient’s perspective are scarce, but is an essential step before implementing these algorithms
as digital filters in the referral process of GPs. [20–21]
In this study we assessed the effect of implementing a referral algorithm in primary care on
disability caused by CLBP by using the Case Finding Axial Spondyloarthritis (CaFaSpA) algo-
rithm: a validated and easy to use, non-invasive algorithm for the PC setting. [3,4]
Methods
Study design
The IMPACT study followed a cluster randomized controlled trial design (trial registration
number: NCT01944163, Clinicaltrials.gov), which was carried out in the PC setting in The
Netherlands. Each cluster contained the GPs from a single PC practice and their included
patients. [22]
This study was approved by the medical ethics committee of the Maasstad Hospital in
Rotterdam, The Netherlands (Trial registration number: 201340).
Participants. Dutch rheumatologists, widely spread over The Netherlands (Rotterdam,
Breda, Groningen and Nijmegen), were invited to participate. General practices in the
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surrounding areas of participating Dutch rheumatologists were invited to participate by letter
or personally. The exclusion criterion for general practices was lack of usage of the Interna-
tional Classification of Primary Care (ICPC) coding system for their patients. [23]
Patients between 18–45 years who had current low back pain (LBP) for more than 12
weeks, and were registered by means of the ICPC code L03 (LBP without radiation) were
invited to participate by a research assistant. Patients willing to participate signed an informed
consent form and were contacted to check in- and exclusion criteria and to register the result
of the CaFaSpA referral strategy for referral to a rheumatologist. Patients’ exclusion criteria
were having a clear medical explanation for the back pain (e.g. trauma, hernia nuclei pulposi),
being mentally incompetent or having insufficient understanding of the Dutch language (writ-
ten). The recruitment period of patients was between 10 September 2014 and 6 November
2015. Depending on the recruitment date patients were followed for four months. Follow-up
period ranged between 10 January 2015 and 6 March 2016.
Cluster randomization. The block randomization schedule was computer generated and
conducted by an independent person, who was not involved in patient care. Randomization
was stratified for the number of GPs working in the general practices (one or two vs. more
than two) to ensure a similar number of patients in both groups. Patients and GPs were
unblinded, because of the nature of the intervention.
Intervention. The intervention was the use of the digital CaFaSpA referral strategy. In
the control group usual primary care was based on the Dutch guideline for LBP. [24] The
CaFaSpA referral strategy consists of four parameters: inflammatory back pain (IBP), a posi-
tive family history of axSpA, a positive response to treatment with NSAID’s and a duration
of back pain for more than 5 years. [3,4] IBP is a questionnaire and all other three variables
are-questions that a GP can apply when a CLBP patient visits their practice units. [4] If at
least-two out of four referral items are present, referral to a rheumatologist is advised in the
intervention group (Table 1). In an external validation study, the CaFaSpA referral strategy
had a sensitivity of 75% and specificity of 58%.
In the usual care group, GPs took care of their patients as usual. Due to ethical reasons the
score of the CaFaSpA referral strategy was given to both the GP and patient at the end of the 4
months follow-up period.
Outcome measures. Our primary outcome was disability caused by CLBP, measured
with the Roland Morris Disability Questionnaire (RMDQ) at baseline and 4 months. In the
developmental phase of this study the RMDQ is regarded as a clinically relevant outcome
measure for low back pain patients and used in clinical trials within this population.
The RMDQ consists of 24 statements about disability caused by LBP and has a scale of 0 to
24. [25] A higher score indicates a more severe disability. [26] The RMDQ was captured via
questionnaires that were sent by email or post.
Secondary outcome was axSpA diagnosis made by a rheumatologist in the intervention
group. The number of referrals to a rheumatologist was also assessed. Rheumatologists in this
study performed their usual daily clinical practice. If patients did not seek a rheumatologist,
Table 1. The CaFaSpA referral strategy.
Positive ASAS IBP questionnaire
Positive family history for spondyloarthritis
Good reaction to NSAIDs
LBP > 5years
If at least two out of the four referral parameters are present a referral to the rheumatologist is advised.
https://doi.org/10.1371/journal.pone.0227025.t001
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despite of our referral advice, we registered the reasons for not visiting the rheumatologist as
much as possible.
Sample size. For the power calculation we assumed a minimal clinical difference of 2.5
points in the RMDQ score after 4 months. [27–29] A value of 6.0 was assumed for the stan-
dard deviation, as found in the previous CaFaSpA study. [4] Without clustering, we esti-
mated 180 patients (90 per arm) would be required to detect a minimal difference of 2.5
RMDQ; with 80% power, using a 2-sided 2 sample t-test at a 0.05 significance level. The
effect of the referral strategy can only be assessed in patients with a positive result of the
referral strategy. As in the previous CaFaSpA studies about 50% of patients scored positive
on the referral strategy [3–4], a total number of 180 patients per arm would be required.
Initially, an average cluster size of 16 patients was expected, while the intra-cluster correla-
tion coefficient was assumed to be 0.05. [30] Hence, to account for clustering, the design
effect was calculated as 1 + (16–1) � 0.05 = 1.75. Multiplying 180 patients per arm by 1.75
implied that a total number of 315 patients per arm should be included. When also assum-
ing a lost-to-follow-up rate of 25% a total number of 840 patients (420 per arm) was initially
calculated as the target for inclusion. [22] However, during the inclusion period of the study
the average cluster size [7] was found to be substantially smaller than was initially expected
[16]. Therefore a small adjustment to the required sample size was applied. The new design
effect was recalculated as 1 + (7–1) � 0.05 = 1.3. This yielded a total sample size of 624
patients after applying the updated design effect and accounting for 25% lost-to-follow-up.
Statistical analysis
STATA/SE 14.2 was used for data analyses. Descriptive statistics were performed to describe
the baseline characteristics. The difference over time between the two groups were analyzed by
a linear mixed-effects model using maximum likelihood estimation. Fixed effects included
allocation group, result of the referral strategy (positive or negative referral strategy) and their
interaction. A random intercept was included for general practice to take clustered randomiza-
tion into account. This random intercept stand for the effect of different PC practices (i.e. clus-
ters). This random intercept parameter can be interpreted as the variance of the deviances of
the cluster-specific intercepts to the overall mean (the intercept estimated in the fixed effects).
Hence one random intercept term may account for an arbitrary number of clusters. Repeated
measures within patients (outcome measured at baseline and after 4 months) were modeled by
an unstructured covariance structure.
The linear mixed model allows for patients to have a missing outcome at either baseline
visit or after 4 months (but not all (both) visits) and yields unbiased estimates. A sub-analysis
within the intervention group was performed to investigate the effect of our model on RMDQ
scores in patients who received a positive or negative referral advice. Finally, a sensitivity anal-
ysis was solely performed within patients who responded positively to NSAIDs in order to
examine a potential effect among the intervention and usual care group. In all analyses, a p-
value < 0.05 was considered statistically significant.
Results
A total of 140 GPs (93 general practices) out of 1145 invited GPs were willing to participate
(Fig 1). Following randomization of these 93 clusters, 47 general practices were assigned to
the intervention group and 46 to the control group. Within these 93 clusters a total of 6010
patients were invited to participate, and 1576 responded to our invitation (intervention group
n = 800 patients (25%), control group n = 776 patients (27%)). After checking the inclusion
criteria by a research assistant, informed consent was obtained from 333 patients in the
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intervention group and from 346 patients in the control group. One cluster in the usual care
group fell out because patients were either [1] not willing to participate [2] has no CLBP, [3]
has trauma/HNP, [4] language barrier. This has led to a cluster size of 45 in the usual care
group and a total of 679 patients and finally 92 clusters. The overall mean cluster size was 7.4
patients (SD 5.2).
Fig 1. Recruitment flowchart impact study.
https://doi.org/10.1371/journal.pone.0227025.g001
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Baseline characteristics
The baseline characteristics of patients are shown in Table 2. Overall, our study population
consisted of 64% women. The mean age was 36.2 years (SD 7.5) and the median duration of
LBP was 10 years (interquartile range (IQR) 4–15 years). Approximately sixty percent of the
patients had a positive outcome of the CaFaSpA referral strategy. The median RMDQ score at
baseline was 8 (IQR 4–12) in both groups. In a sensitivity analysis we checked whether positive
NSAIDs responders could have influenced our results. However, from our comparative analy-
ses in baseline characteristics including age, gender, LBP duration, and NSAIDs use and dos-
age no significant differences were present between the intervention and usual care group
(data not shown).
Primary endpoint
In total, 577 patients (85%) completed the RMDQ at baseline and 484 (84%) patients com-
pleted the RMDQ after 4 months. At baseline the mean RMDQ score was 8.39 (7.59–9.18) in
the intervention group and 8.61 (7.83–9.39) in the control group. At four months the mean
RMDQ score for the intervention and control group was 7.65 (6.79–8.50) and 8.15 (7.34–8.96)
respectively.
A linear mixed-effects regression model was performed on 597 individual patients (47%
intervention, 53% control), with at least one available RMDQ score (Fig 2). The mean dif-
ference of 0.28 between the groups was not statistically significant (p-value 0.50). Fig 3
shows the sub-analysis of the intervention group. The absolute mean decreases in RMDQ
scores between the patients who received either a positive or negative referral advice was
similar.
Table 2. Baseline patient characteristics.
Use of referral strategy (n = 333) Usual care (n = 346)
Number of clusters 47 45
Cluster size, mean ± SD 7.1 ± 4.9 7.7 ± 5.5
Age, year mean ± SD 36.7 ± 7.1 35.8 ± 7.8
Male sex, n (%) 115 (35) 130 (38)
CLBP duration, year median (IQR) 10 (4–15) 9 (4–15)
RMDQ, median (IQR) 8 (4–12) 8 (4–12)
VAS pain, median (IQR) 5 (3–7) 6 (3–7)
QoL mean ± SD 0.69 ± 0.26 0.70 ± 0.26
NSAID use, n (%) 88 (53) 87 (49)
Individual components of referral model
Inflammatory back pain, n (%) 115 (35) 128 (37)
Positive family history, n (%) 82 (25) 71 (21)
Positive response to NSAIDs�, n (%) 154 (46) 192 (55)
CLBP� 5 years 233 (70) 249 (72)
Positive referral model, n (%) 192 (58) 216 (62)
LBP: low back pain. CLBP: chronic low back pain. IQR: interquartile range. RMDQ: Roland Morris Disability
Questionnaire. VAS: visual analog scale. Cluster size = number of patients. QoL: Quality of life measured with the
EQ-5D.
�Positive NSAIDs response according to patients.
https://doi.org/10.1371/journal.pone.0227025.t002
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Secondary endpoint
In total, 192 (58%) of the 333 patients in the intervention group received a positive referral
advice based on the CaFaSpA rule. Of those finally 103 patients (54%) visited a rheumatologist.
Out of the 103 patients we could only verify visits of 75 (73%) patients by receiving their hospi-
tal records. Six patients out of these 75 (8%) received the diagnosis axSpA from the rheumatol-
ogist. Among those patients one patient was treated with anti-TNF (Humira) and five patients
received NSAIDs. The median RMDQ score among patients who visited the rheumatologist
decreased from 8 to 5 after four months (p-value 0.17) (Fig 4).
Discussion
In a previous prospective study the CaFaSpA referral strategy showed to be potentially effi-
cient and discriminative for the identification of axSpA patients in a CLBP population.
Therefore, we performed the current impact analysis, which is an essential step before imple-
mentation in daily practice. In this clustered randomized study, the CaFaSpA referral strat-
egy did not have an effect on disabilities caused by CLBP compared to usual primary care
after 4 months follow-up period. Although a small decrease in RMDQ scores was detected
after 4 months, none of the patient groups reached a clinically meaningful decrease in
RMDQ score of 2.5–5 points as described by previous studies. [27,28] To our knowledge this
is the first study that examined the effect of a referral strategy for CLBP and for axSpA in
daily clinical practice.
Fig 2. Estimated mean RMDQ scores over time for the overall intervention and usual care group. Bars indicate 95% confidence intervals for the mean
estimates.
https://doi.org/10.1371/journal.pone.0227025.g002
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The lack of differences between the intervention and usual care groups might have been
induced by a considerable short follow-up time as detectable treatment effects may take longer
than 4 months. The first step in treatment is using at least two types of highly dosed NSAIDs
for at least 4 weeks. When both treatments fail then anti-TNF alpha can be considered. It is
expected that the difference between the two groups will be more obvious after a longer fol-
low-up period of 12 months. In addition, we may have created awareness amongst GPs for
axSpA or LBP complaints, even in the usual care group. Patients in the usual care group could
have possibly received education, physiotherapy and advice in lifestyle to improve their CLBP,
which might have positively influenced their RMDQ score.
Fortunately, the CaFaSpA referral strategy was able to identify newly diagnosed axSpA
patients (8%), who had otherwise never been diagnosed and treated as described according
to the international guideline. [31] This percentage is comparable to the minimally reported
prevalence of axSpA among CLBP patients. [2] The lack of overall difference between the
referred and usual care group might have been induced by the low prevalence of axSpA. The
axSpA diagnosis in our study is lower than in the previously reported CaFaSpA studies (16%
and 24%). [3,4]
In this study axSpA diagnose was made by a rheumatologist which reflects daily clinical
practice. Currently we only have a classification criteria (ASAS) for axSpA and diagnostic
criteria are still lacking.
The present study has some strengths and limitations. The strengths of our study are multi-
fold. First, an impact analysis of a referral strategy for axSpA in PC has not been performed
previously. Secondly, the design of this study as a clustered randomized trial is considered as
Fig 3. Difference in mean RMDQ scores over time within the intervention group, for patients receiving positive and negative referral strategy. Bars indicate
95% confidence intervals for the mean estimates.
https://doi.org/10.1371/journal.pone.0227025.g003
IMPACT of a referral algorithm for axial spondyloarthritis
PLOS ONE | https://doi.org/10.1371/journal.pone.0227025 January 28, 2020 8 / 12
the most suitable design to address this research question. Thirdly, we were able to include
clusters with an equal number of participating patients in both groups (intervention and usual
care). The statistical analyses, by using a linear mixed-effects regression model, take the cluster
randomized nature of the study into account and is able to handle missing outcomes. Fourthly,
in the present study we investigated the impact of the CaFaSpA referral strategy by means of
patient relevant health outcomes (disability caused by CLBP). Overall, by using the CaFaSpA
referral strategy, 42% of patients received a negative referral advice, who would otherwise be
seen by a rheumatologist when the ASAS recommendation for CLBP was followed. [16] The
ASAS referral strategy recommends that all CLBP patients with one axSpA feature should be
referred to the rheumatologist. This would mean that almost all CLBP patients should be
referred to a rheumatologist. Therefore, the CaFaSpA model can be used as an easy to use,
non-expensive screening model in PC to identify young CLBP patients at risk for axSpA.
Finely, results of this study are generalizable since our baseline characteristics (including
age, gender and LBP duration) and RMDQ scores are comparable with other Dutch studies
in PC setting in patients with CLBP, where scores between 6 and 7 have been reported. [4,29]
Some limitations must also be addressed. First, NSAIDs use at baseline may have affected
our estimates as NSAID’s are an over the counter medication in The Netherlands. However,
Fig 4. Scatter plot of the RMDQ scores at baseline and after 4 months in the intervention group in patients with a positive referral advice.
https://doi.org/10.1371/journal.pone.0227025.g004
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our sensitivity analysis did not reveal any difference with regard to patient characteristics or
clinically relevant parameters in those who had a good response to NSAIDs. Second, decisions
not to seek a rheumatologist were made both at the patient’s and GP level. Despite fulfillment
of the CaFaSpA referral advise, 39% of the patients either chose not to visit the rheumatologist
due to financial reasons or because they personally did not suspect that their back pain was
caused by axSpA. On the other hand, patients were advised by their GP not to seek the rheu-
matologist because the GP does not suspect an axSpA diagnose. Moreover, in those who had
been referred to rheumatologist, the advised diagnostic workup of axSpA was not fully fol-
lowed. This approach could have influenced our results. For example, only 89% of the patients
had a conventional X-ray of the sacroiliac joints and in all patients at least two features were
present. Therefore, HLA-B27 positivity or sacroiliitis on MRI should have been tested. [32]
Finally, we want to highlight that the expected changes of disability would be much higher if
treatment with TNF blockers would have been started.
However, four months follow-up is too short period for a patient to visit a rheumatologist,
fail on two different NSAIDs and start biologicals.
In conclusion, the CaFaSpA referral strategy for axSpA did not have an impact on disability
after four months caused by CLBP. However, it might still be used as a screening model for
primary care to identify CLBP patients at risk for axSpA. We finally want to emphasize that
impact studies on outcomes that really matter to patients should be performed before imple-
menting these referral models in daily practice.
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